Streetbeat News

Revenues

BMRN

Biomarin Pharmaceutical (NASDAQ:BMRN) reported Q1 adjusted earnings of $0.71 per share, surpassing the $0.34 estimate, marking a 108.82% beat and an 18.33% increase from last year's $0.60. However, their Q1 sales of $648.83M fell short of the $651.79M estimate by 0.45%, though it's an 8.79% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 8:05 pm

HAL

Recent analyst ratings for Halliburton (NYSE:HAL) show a positive trend, with 5 analysts offering perspectives ranging from bullish to somewhat bullish over the last three months. The average 12-month price target for HAL has been raised to $48.2, reflecting a 2.55% increase from the previous target of $47.00. Halliburton's financial performance includes a revenue growth rate of 2.81% for the last quarter of 2023, a net margin of 11.52%, and an ROE of 7.13%, indicating strong profitability and financial management despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 7:01 pm

RLI

RLI Corp (NYSE:RLI) has been analyzed by 4 analysts, showing a mix of bullish and indifferent sentiments. Recent updates include raised price targets, with an average 12-month target of $161.5, reflecting a 3.97% increase from the previous $155.33. The company's financial performance is strong, with significant revenue growth, high net margin, and efficient asset and equity management, positioning it favorably among peers.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 7:01 pm

CR

Analyst ratings for Crane (NYSE:CR) have shown a positive trend over the past three months, with all four analysts giving bullish ratings. The average 12-month price target for Crane has been raised to $151.75, indicating a 13.04% increase from the previous target of $134.25. Crane's financial performance includes a revenue growth of 9.67% as of December 31, 2023, but it faces challenges with below-industry averages in net margin, ROE, and ROA. The company's debt management is seen as prudent with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 7:00 pm

BIIB

ESALY

Leqembi, an Alzheimer's drug developed by Eisai Limited (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB), is experiencing slow adoption nine months post-U.S. launch due to skepticism among doctors about its efficacy, costs, and risks. Despite FDA approval and showing a 27% slowdown in cognition decline, less than half of U.S. neurologists recommend it, citing limited patient benefit and significant risks, including potential brain swelling and bleeding. The drug's high cost and the need for regular MRIs and bi-monthly infusions add to the concerns. Eisai and Biogen aim to increase their sales force by 30% to reach 100,000 patients by 2026, despite only a couple thousand patients starting treatment as of January.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:23 pm

LLY

NVO

The Senate Committee on Health, Education, Labor, and Pensions is investigating Novo Nordisk's pricing strategies for its medications Ozempic and Wegovy, amid concerns over their affordability and pricing discrepancies between the U.S. and other countries. Senator Bernie Sanders has also expressed intentions to scrutinize Eli Lilly's pricing for its medications, highlighting an industry-wide issue. The potential expansion of Medicare coverage for Wegovy could significantly impact Medicare beneficiaries with heart conditions and obesity, with broader coverage possibly anticipated by 2025.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:14 pm

BGNE

Six financial analysts have recently published diverse ratings on BeiGene (NASDAQ:BGNE), ranging from bullish to bearish, with an average 12-month price target of $212.88, a decrease from the prior target. The ratings reflect adjustments based on market dynamics and company performance. BeiGene, a biotech firm focused on cancer treatment drugs, shows significant revenue growth but struggles with profitability and efficiency metrics. The company's market capitalization and financial ratios indicate a smaller scale and conservative financial approach compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:01 pm

GH

Guardant Health (NASDAQ:GH) has been analyzed by 7 analysts, showing a mix of bullish and somewhat bullish ratings with no bearish or indifferent stances. The 12-month price targets have seen a downward revision, with the current average target at $35.71, down 20.06% from the previous $44.67. Analysts from firms like Craig-Hallum, Goldman Sachs, Piper Sandler, JP Morgan, and Canaccord Genuity have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Guardant Health, a leader in liquid biopsy tests, has shown a solid revenue growth rate of 22.19% as of December 31, 2023, but faces challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:01 pm

RBA

Analysts have mixed views on RB Global (NYSE:RBA), with recent ratings ranging from bullish to bearish. The average 12-month price target has been raised to $86.5, reflecting a 10.54% increase from the previous target. RB Global, a leader in heavy equipment auctions, has shown strong financial performance with significant revenue growth and profitability. The company's market capitalization and financial metrics like net margin and ROE outperform industry averages, although its ROA is below standard.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:01 pm

CALX

9 analysts have recently updated their ratings on Calix (NYSE:CALX), showing unanimous bullish sentiment despite lowering their 12-month price targets, reflecting a 10.6% decrease from previous estimates. The average target now stands at $45.44, with adjustments made due to market conditions and company performance. Calix's financial health indicators such as revenue growth and net margin outperform industry benchmarks, though its ROE and ROA are below average, suggesting challenges in capital and asset efficiency.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 6:01 pm